Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 4, 2006, Pages 487-493

  Jensen, Søren Astrup ^a   Sørensen, Jens Benn ^a  

^a University of Copenhagen   (Denmark)

Author keywords

5 Fluorouracil; Beta blockers; Calcium channels blockers; Capecitabine; Cardiotoxicity; Nitrates

Indexed keywords

CAPECITABINE; CARBOPLATIN; FLUOROURACIL; FOLINATE CALCIUM; GLYCERYL TRINITRATE; OXALIPLATIN; PRODRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COLORECTAL CANCER; COMORBIDITY; FEASIBILITY STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; KIDNEY CLEARANCE; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SOLID TUMOR; STOMACH CANCER;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ATHEROSCLEROSIS; COMORBIDITY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; HEART DISEASES; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; NITROGLYCERIN; RETROSPECTIVE STUDIES; RISK FACTORS; VASODILATOR AGENTS;

EID: 33745712231     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0178-1     Document Type: Article

References (32)

1. Wacker A, Lersch C, Scherpinski U, Reindl L, Seyfarth M (2003) High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. Oncology 65:108-112
2. Tsavaris N, Kosmas C, Vadiaka M, Efremidis M, Zinelis A, Beldecos D, Sakelariou D, Koufos C, Stamatelos G (2002) Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy - a survey of 427 patients. Med Sci Monit 8:I51-I57
3. Keefe DL, Roistacher N, Pierri MK (1993) Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol 33:1060-1070
4. Schober C, Papageorgiou E, Harstrick A, Bokemeyer C, Mugge A, Stahl M, Wilke H, Poliwoda H, Hiddemann W, Kohne-Wompner CH (1993) Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 72:2242-2247
5. Labianca R, Beretta G, Clerici M, Fraschini P, Luporini G (1982) Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumor 68:505-510
6. Robben NC, Pippas AW, Moore JO (1993) The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 71:493-509
7. De Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L, Canal P, Chevreau C, Carrie D, Soulie P (1992) Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 10:1795-1801
8. Jeremic B, Jevremovic S, Djuric L, Mijatovic L (1990) Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin. J Chemother 2:264-267
9. Akhtar SS, Salim KP, Bano ZA (1993) Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 50:441-444
10. Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM (1993) In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 53:3028-3033
11. Porta C, Moroni M, Ferrari S, Nastasi G (1998) Endothelin-1 and 5-fluorouracil-induced cardiotoxicity. Neoplasma 45:81-82
12. Kohne CH, Thuss-Patience P, Friedrich M, Daniel PT, Kretzschmar A, Benter T, Bauer B, Dietz R, Dorken B (1998) Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. Br J Cancer 77:973-977
13. Kuzel T, Esparaz B, Green D, Kies M (1990) Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 65:885-889
14. Matsubara I, Kamiya J, Imai S (1980) Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol 30:871-879
15. Lemaire L, Malet-Martino MC, Longo S, Martino R, De Forni M, Carton M (1991) Fluoroacetaldehyde as cardiotoxic impurity in fluorouracil (Roche). Lancet 337:560
16. Burger AJ, Mannino S (1987) 5-Fluorouracil-induced coronary vasospasm. Am Heart J 114:433-436
17. Mizuno Y, Hokamura Y, Kimura T, Kimura Y, Kaikita K, Yasue H (1995) A case of 5-fluorouracil cardiotoxicity simulating acute myocardial infarction. Jpn Circ J 59:303-307
18. Eskilsson J, Albertsson M (1990) Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol 29:1001-1003
19. Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215-237
20. Eskilsson J, Albertsson M, Mercke C (1988) Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil. Radiother Oncol 13:41-46
21. Rezkalla S, Kloner RA, Ensley J, al Sarraf M, Revels S, Olivenstein A, Bhasin S, Kerpel-Fronious S, Turi ZG (1989) Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 7:509-514
22. Lestuzzi C, Viel E, Picano E, Meneguzzo N (2001) Coronary vasospasm as a cause of effort-related myocardial ischemia during low-dose chronic continuous infusion of 5-fluorouracil. Am J Med 111:316-318
23. McDermott BJ, van den Berg HW, Murphy RF (1982) Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. Cancer Chemother Pharmacol 9:173-178
24. Lee JS, Dhingra HM, Chiuten DF, Holoye PY, Jeffries D, Murphy WK, Umsawasdi T, Neidhart JA (1987) Phase II pilot study with cisplatin, etoposide, and continuous-infusion 5-fluorouracil in metastatic non-small cell lung cancer. Am J Clin Oncol 10:512-514
25. Martin M, Diaz-Rubio E, Furio V, Blazquez J, Almenarez J, Farina J (1989) Lethal cardiac toxicity after cisplatin and 5-fluorouracil chemotherapy. Report of a case with necropsy study. Am J Clin Oncol 12:229-234
26. Prevost A, Merol JC, Aime P, Moutel K, Roger-Liautaud F, Nasca S, Legros M, Coninx P (2005) A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck. Oncol Rep 14:771-776
27. Yip D, Karapetis C, Strickland AH, Steer C, Holford C, Knight S, Harper P (2003) A dose-escalating study of oral eniluracil/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies. Ann Oncol 14:864-866
28. Guo XD, Harold N, Saif MW, Schuler B, Szabo E, Hamilton JM, Monahan BP, Quinn MG, Cliatt J, Nguyen D, Grollman F, Thomas RR, McQuigan EA, Wilson R, Takimoto CH, Grem JL (2003) Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. Cancer Chemother Pharmacol 52:79-85
29. Marsh JC, Catalano P, Huang J, Graham DL, Cornfeld MJ, O'Dwyer PJ, Benson AB III (2002) Eastern cooperative oncology group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. Clin Colorectal Cancer 2:43-50
30. van Kuilenburg AB, Meinsma R, Zoetekouw L, van Gennip AH (2002) Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14 + 1g > a mutation. Int J Cancer 101:253-258
31. Celik I, Kars A, Guc D, Tekuzman G, Ruacan S (2002) Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients. Cancer Invest 20:333-339
32. Di Paolo A, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G, Allegrini G, Mini E, Bocci G, Conte PF, Del Tacca M (2001) Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 12:1301-1306